Apimeds Pharmaceuticals US (APUS) Free Cash Flow (2024 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Free Cash Flow came in at -$3.8 million in Q4 2025, down 3754.43% on a YoY basis from $105067.8 in Q4 2024, and down 119.57% quarter-over-quarter from -$1.7 million in Q3 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Free Cash Flow (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Free Cash Flow for 2 consecutive years, with -$3.8 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow fell 3754.43% year-over-year to -$3.8 million; the trailing twelve-month figure through Dec 2025 stood at -$9.0 million (down 1122.83% YoY), and the FY2025 full-year result was -$9.0 million, down 1124.65% from the prior year.
- Free Cash Flow fell to -$3.8 million in Q4 2025 per APUS's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$20313.0 in Q1 2025 and bottomed at -$3.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Apimeds Pharmaceuticals US | 3.65 Mn | 3.65 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -3.84 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | -3.36 Mn |
| Mar 31, 2025 | -20,313.00 |
| Dec 31, 2024 | -99,616.00 |
| Sep 30, 2024 | -186,755.00 |
| Jun 30, 2024 | -184,055.00 |
| Mar 31, 2024 | -263,100.00 |